Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Convatec Group Plc | LSE:CTEC | London | Ordinary Share | GB00BD3VFW73 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.20 | 0.08% | 258.40 | 257.80 | 258.00 | 260.00 | 256.60 | 258.20 | 1,786,507 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 2.29B | 190.5M | 0.0929 | 27.77 | 5.29B |
TIDMCTEC
RNS Number : 3391L
ConvaTec Group PLC
12 May 2022
ConvaTec Group Plc
Results of Annual General Meeting
Reading, United Kingdom (12 May 2022) - Poll Result
ConvaTec Group Plc ("ConvaTec") held its Annual General Meeting today ("AGM"). The results of the poll held in relation to the resolutions proposed at the AGM are set out below
For (see note Against (see Votes % of Votes 2) note 2) Total ISC Witheld Voted Resolution No of shares % No of % Shares ------------------- -------- -------------------- ------- ------------------- Receive Annual Report 1 and Accounts 1,827,980,026 99.99% 138,955 0.01% 1,828,118,981 89.85% 2,678,250 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Approve the Directors' Remuneration 2 Report 1,310,074,242 72.51% 496,566,511 27.49% 1,806,640,753 88.80% 24,156,478 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Declare Final 3 Dividend 1,828,471,889 99.87% 2,318,530 0.13% 1,830,790,419 89.98% 6,812 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Re-elect John McAdam as a 4 director 1,785,547,176 97.61% 43,742,972 2.39% 1,829,290,148 89.91% 1,507,083 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Re-elect Karim Bitar as a 5 director 1,824,546,868 99.66% 6,234,317 0.34% 1,830,781,185 89.98% 16,046 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Re-elect Margaret Ewing 6 director 1,808,325,168 98.77% 22,443,302 1.23% 1,830,768,470 89.98% 28,761 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Re-elect Brian May as a 7 director 1,713,823,773 94.03% 108,742,705 5.97% 1,822,566,478 89.58% 8,230,753 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Re-elect Sten Scheibye as a 8 director 1,824,824,180 99.68% 5,944,289 0.32% 1,830,768,469 89.98% 28,762 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Re-elect Heather Mason as 9 a director 1,812,618,794 99.01% 18,149,676 0.99% 1,830,768,470 89.98% 28,761 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Re-elect Professor Constantin Coussios as a 10 director 1,811,236,685 98.93% 19,521,954 1.07% 1,830,758,639 89.98% 38,592 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Elect Jonny Mason as 11 a director 1,819,579,146 99.39% 11,187,969 0.61% 1,830,767,115 89.98% 30,116 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Elect Kim Lody as 12 a director 1,824,822,794 99.68% 5,812,573 0.32% 1,830,635,367 89.98% 161,864 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Elect Sharon O'Keefe as a 13 director 1,824,954,544 99.68% 5,812,573 0.32% 1,830,767,117 89.98% 30,114 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Re-appoint Deloitte LLP as 14 auditors 1,828,465,498 99.95% 830,907 0.05% 1,829,296,405 89.91% 1,500,826 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Authorise the Directors to agree the auditors' 15 remuneration 1,830,098,448 99.96% 671,868 0.04% 1,830,770,316 89.98% 26,915 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Authorise political donations and political 16 expenditure 1,814,389,000 99.12% 16,165,069 0.88% 1,830,554,069 89.97% 241,662 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Authorise allotment 17 of shares 1,737,684,352 94.92% 93,082,507 5.08% 1,830,766,859 89.98% 30,372 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Renew the Scrip Dividend 18 Scheme. 1,830,739,805 100.00% 22,649 0.00% 1,830,762,454 89.98% 34,777 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Disapply pre-emption 19 rights* 1,796,085,428 98.35% 30,153,440 1.65% 1,826,238,868 89.76% 4,558,363 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Disapply pre-emption rights in connection with an acquisition or specified capital 20 investment* 1,773,062,102 97.09% 53,175,701 2.91% 1,826,237,803 89.76% 4,559,428 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Authorise purchase of own 21 shares* 1,828,587,725 99.91% 1,634,548 0.09% 1,830,222,273 89.96% 574,958 ------------- ------------------- -------- -------------------- ------- ------------------- ------- ------------------- Call general meetings on 14 days' 22 notice* 1,726,127,643 94.28% 104,652,489 5.72% 1,830,780,132 89.98% 17,099 ------------- ------------------- -------- -------------------- ------- ------------------- ------- -------------------
*Special Resolution
NOTES:
1. All resolutions were passed. 2. Votes "For" and "Against" are expressed as a percentage of votes received.
3. A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
4. Total number of shares in issue at close of business on 10 May 2022 was 2,034,572,935 shares. 89.88% of capital was voted.
5. Computershare acted as scrutineer of the poll on all resolutions.
In accordance with Listing Rule 9.6.2, copies of the resolutions that do not constitute ordinary business that were passed at the annual general meeting have been submitted to the National Storage Mechanism and will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
AGM - Resolution Two
The Board notes the voting result in relation to Resolution 2 at today's Annual General Meeting. We are grateful for the feedback and indications of support received from shareholders in advance of the Meeting and will continue to engage with shareholders who were unable to support this resolution, in order to understand their views in advance of publishing an update statement within six months of today. The Board also plans to engage with shareholders later in the year on the Remuneration Policy which will be subject to approval at the 2023 AGM.
Board Changes
As previously announced, Dr Regina Benjamin did not stand for re-election at the AGM. Sharon O'Keefe has been appointed as ConvaTec's designated Non-Executive Director for workforce engagement with effect from 13 May 2022. This statement is made in accordance with Listing Rule 9.6.11.
Enquiries
Analysts and Investors
Kate Postans, Vice President, Investor Relations +44 (0)7826 447 807
ir@convatec.com
Media
Buchanan: Charles Ryland / Chris Lane +44 (0)207 466 5000
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
# # #
END
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGUUAVRUBUVAAR
(END) Dow Jones Newswires
May 12, 2022 11:25 ET (15:25 GMT)
1 Year Convatec Chart |
1 Month Convatec Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions